Literature DB >> 7475551

Cancer progression and p53.

D A Carson1, A Lois.   

Abstract

In a complex organism, somatic cells are under intermittent selection pressure for the emergence of mutants that can survive environmental insults and that can grow autonomously despite adverse conditions. Repeated rounds of mutation, selection, and proliferation may lead to cancer. The organism prevents malignant transformation by assuring accurate DNA repair before cell division, by forcing the death of cells with excessive DNA damage, and by placing limits on the replicative lifespans of most somatic cells. The p53 gene is a "guardian of the genome"--it regulates multiple components of the DNA damage control response and promotes cellular senescence. Disabling mutations and deletions of p53 occur in 50% of human tumours. p53-deficient cancers are often unstable, aggressive, and resistant to therapy.

Entities:  

Mesh:

Year:  1995        PMID: 7475551     DOI: 10.1016/s0140-6736(95)91693-8

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  38 in total

1.  Expression of molecular biomarkers in primary breast tumors implanted into a surrogate host: increased levels of cyclins correlate with tumor progression.

Authors:  G Wani; I Noyes; G E Milo; S M D'Ambrosio
Journal:  Mol Med       Date:  1997-04       Impact factor: 6.354

Review 2.  Apoptosis: molecular mechanisms and implications for cancer chemotherapy.

Authors:  H J Guchelaar; A Vermes; I Vermes; C Haanen
Journal:  Pharm World Sci       Date:  1997-06

3.  A novel lipopolysaccharide-induced transcription factor regulating tumor necrosis factor alpha gene expression: molecular cloning, sequencing, characterization, and chromosomal assignment.

Authors:  F Myokai; S Takashiba; R Lebo; S Amar
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-13       Impact factor: 11.205

4.  p53 mutations are associated with dysplasia and progression of dysplasia in patients with Crohn's disease.

Authors:  Jeffrey W Nathanson; Nicole E Yadron; Jeanne Farnan; Sydney Kinnear; John Hart; David T Rubin
Journal:  Dig Dis Sci       Date:  2007-08-04       Impact factor: 3.199

Review 5.  The nucleolus—guardian of cellular homeostasis and genome integrity.

Authors:  Ingrid Grummt
Journal:  Chromosoma       Date:  2013-12       Impact factor: 4.316

6.  P53 expression in stage I squamous cell lung cancer.

Authors:  J Moldvay; J Strausz; M Egerváry; L Agócs; J Bocsi; Z Schaff
Journal:  Pathol Oncol Res       Date:  1998       Impact factor: 3.201

Review 7.  Biology of colorectal cancer in ulcerative colitis.

Authors:  B A Lashner; B D Shapiro
Journal:  J Gastrointest Surg       Date:  1998 Jul-Aug       Impact factor: 3.452

8.  Bcl-2 and p53 overexpression as associated risk factors in transitional cell carcinoma of the bladder.

Authors:  F Atuğ; L Türkeri; M Ozyürek; A Akdaş
Journal:  Int Urol Nephrol       Date:  1998       Impact factor: 2.370

9.  Glutathione-Scavenging Poly(disulfide amide) Nanoparticles for the Effective Delivery of Pt(IV) Prodrugs and Reversal of Cisplatin Resistance.

Authors:  Xiang Ling; Xing Chen; Imogen A Riddell; Wei Tao; Junqing Wang; Geoffrey Hollett; Stephen J Lippard; Omid C Farokhzad; Jinjun Shi; Jun Wu
Journal:  Nano Lett       Date:  2018-06-19       Impact factor: 11.189

10.  Synergistic anticancer effect of exogenous wild-type p53 gene combined with 5-FU in human colon cancer resistant to 5-FU in vivo.

Authors:  Qi Xie; Min-Yi Wu; Ding-Xuan Zhang; Yi-Ming Yang; Bao-Shuai Wang; Jing Zhang; Jin Xu; Wei-De Zhong; Jia-Ni Hu
Journal:  World J Gastroenterol       Date:  2016-08-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.